Yang Feng, Chen Quan-Fang
Department of Emergency, the First Affiliated Hospital of Guangxi Medical University.
Department of Respiratory Medicine, Institute of Respiratory Disease, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Anticancer Drugs. 2023 Feb 1;34(2):302-305. doi: 10.1097/CAD.0000000000001417. Epub 2023 Nov 17.
Non-small cell lung carcinoma (NSCLC) is a complex disease, with many different potential gene mutations that drive its formation, occurrence, and development. It is estimated that about 3% of NSCLC patients are accompanied by MET exon 14 skipping (METex14) mutations, and the prognosis of such patients is generally poor, which forms a formidable challenge for us. Savolitinib (Orpathys) is the first highly selective MET inhibitor in China. Here, we presented an NSCLC patient with MET∆ex14 mutation, who was initially uncertain whether existed intrapulmonary metastasis and recently underwent percutaneous coronary intervention for acute myocardial infarction and received savolitinib 600 mg once a day. The tumor was significantly shrunk 6 months later, and no metastatic lesions were found. Eventually, it was determined that the patient was in the early stage of lung cancer. After experts' consultation and evaluation, the patient accepted radical tumor resection and recovered well. Therefore, savolitinib is an important treatment strategy for NSCLC patients with MET∆ex14 mutation, who was not suitable for surgery. Our experience may provide supporting evidence and guidance for implementing an effective therapeutic strategy for similar cases.
非小细胞肺癌（NSCLC）是一种复杂的疾病，存在许多驱动其形成、发生和发展的不同潜在基因突变。据估计，约3%的NSCLC患者伴有MET外显子14跳跃（METex14）突变，此类患者的预后通常较差，这给我们带来了巨大挑战。赛沃替尼（沃瑞沙）是中国首个高选择性MET抑制剂。在此，我们报告了1例发生MET∆ex14突变的NSCLC患者，该患者最初不确定是否存在肺内转移，近期因急性心肌梗死接受了经皮冠状动脉介入治疗，并接受赛沃替尼每日1次、每次600 mg治疗。6个月后肿瘤显著缩小，未发现转移病灶。最终确定该患者处于肺癌早期。经专家会诊评估后，患者接受了肿瘤根治性切除术，恢复良好。因此，对于不适合手术的MET∆ex14突变NSCLC患者，赛沃替尼是一种重要的治疗策略。我们的经验可能为实施类似病例的有效治疗策略提供支持证据和指导。
